Download Files:
GSK1795091
$1,593 – $5,075
Products Details
Product Description
– GSK1795091 (CRX-601), an immunologic stimulator, is a synthetic TLR4 agonist. Antitumor activity. GSK1795091 can be used as a vaccine adjuvant to enhance both mucosal and systemic immunity to influenza virus vaccines. Not only, GSK1795091 inhibits tumor growth and increases the survival in mice model, but results in long term survival in influenza challenge model in mice[1][2][3].
Web ID
– HY-111792
Shipping
– Room temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C81H157N2O16P
References
– [1]Hug BA, et al. Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study. Clin Ther. 2020;42(8):1519-1534.e33. |[2]Cebada J, et al. OX40 agonists for cancer treatment: a patent review. Expert Opin Ther Pat. 2021 Jan;31(1):81-90.|[3]Maroof A, et.al. Intranasal vaccination promotes detrimental Th17-mediated immunity against influenza infection. PLoS Pathog. 2014 Jan;10(1):e1003875.
CAS Number
– 1233589-81-5
Molecular Weight
– 1446.09
SMILES
– O=C(C[C@H](OCCCCCCCCCC)CCCCCCCCCCC)O[C@@H]([C@@H]([C@H]1CO)O[P](O)(O)=O)[C@H]([C@@H](O1)OC[C@@H](C(O)=O)NC(C[C@H](OCCCCCCCCCC)CCCCCCCCCCC)=O)NC(C[C@H](OCCCCCCCCCC)CCCCCCCCCCC)=O
Clinical Information
– Phase 1
Research Area
– Cancer; Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– Toll-like Receptor (TLR)
Pathway
– Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
